Long‐term complications in survivors of advanced stage neuroblastoma
The DOI matches its Crossref record.
Abstract
Background: Few studies have assessed late effects in neuroblastoma (NB) survivors, particularly those with advanced stage disease. Methods: Retrospective analysis of a cohort of advanced stage NB survivors followed in a late effect clinic at a single institution. Screening tests to detect late effects were tailored depending on the individual's treatment exposures. Results: The study included 63 survivors (31 males). The median age at diagnosis was 3.0 years. The median follow‐up from diagnosis was 7.06 years. All patients had surgery and received chemotherapy, 89% received radiation therapy (RT), 62% immunotherapy, and 56% autologous stem cell transplant. Late complications were detected in 95% of survivors and included: hearing loss (62%), primary hypothyroidism (24%), ovarian failure (41% of females), musculoskeletal (19%), and pulmonary (19%) abnormalities. The majority of complications were moderate, with only 4% being life‐threatening. Survivors who received cisplatin were at greater risk to develop hearing loss compared to those not so treated (OR 9.74; 95% CI: 0.9–101.6). A total dose of cyclophosphamide greater than 7.4 g was associated with ovarian failure (P = 0.02). Conclusions: Late complications occur frequently in survivors of advanced stage NB. The majority of these problems are of mild‐moderate severity. Long‐term follow‐up (LFTU) and screening of this population is essential. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Self-citationCisplatin is retained in the cochlea indefinitely following chemotherapy
Breglio, A. M., Rusheen, A. E., Shide, E. D., Fernandez, K. A., Spielbauer, K. K., McLachlin, K. M., Hall, M. D., Amable, L., & Cunningham, L. L. (2017) · Nature Communications · doi:10.1038/s41467-017-01837-1 · Cited by 412
Overview and recent advances in the treatment of neuroblastoma
Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S., & Zage, P. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285230 · Cited by 394
Ness, K. K., Mertens, A. C., Hudson, M. M., Wall, M. M., Leisenring, W. M., Oeffinger, K. C., Sklar, C. A., Robison, L. L., & Gurney, J. G. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-9-200511010-00007 · Cited by 328
Self-citationUSP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan, Y.-H., Cheng, J., Vasudevan, S. A., Dou, J., Zhang, H., Patel, R. H., Ma, I. T., Rojas, Y., Zhao, Y., Yu, Y., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.400 · Cited by 199
Metadata
- Authors
- Laverdière, C., Cheung, N. V., Kushner, B. H., Kramer, K., Modak, S., LaQuaglia, M. P., Wolden, S., Ness, K. K., Gurney, J. G., & Sklar, C. A.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2005-02-15
- Volume
- 45
- Issue
- 3
- Pages
- 324-332
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2106739013
- Cited by
- 169
- References
- 0
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.